Evidence map›Paper›PMID 33104704›Full record

ArticlePloS one2020

Automated dry thawing of cryopreserved haematopoietic cells is not adversely influenced by cryostorage time, patient age or gender.

Peter Kilbride, Julie Meneghel, Giovanna Creasey, Fatemeh Masoudzadeh, Tina Drew, Hannah Creasey, David Bloxham, G John Morris, Kevin Jestice

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Cold Chain Delivery in Cell Therapies.Advances in experimental medicine and biology · 2025
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Peter KilbrideCytiva, Danaher Corporation, Cambridge, United Kingdom.
Julie MeneghelCytiva, Danaher Corporation, Cambridge, United Kingdom.ORCID 0000-0002-1510-8642
Giovanna CreaseyCytiva, Danaher Corporation, Cambridge, United Kingdom.
Fatemeh MasoudzadehCytiva, Danaher Corporation, Cambridge, United Kingdom.
Tina DrewCambridge Cellular Therapy Laboratory, Clinical Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Hannah CreaseyHaematopathology and Oncology Diagnostic Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
David BloxhamHaematopathology and Oncology Diagnostic Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
G John MorrisCytiva, Danaher Corporation, Cambridge, United Kingdom.
Kevin JesticeCambridge Cellular Therapy Laboratory, Clinical Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Danaher (United Kingdom) · GBCambridge University Hospitals NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell therapies are becoming increasingly widely used, and their production and cryopreservation should take place under tightly controlled GMP conditions, with minimal batch-to-batch variation. One potential source of variation is in the thawing of cryopreserved samples, typically carried out in water baths. This study looks at an alternative, dry thawing, to minimise variability in the thawing of a cryopreserved cell therapy, and compares the cellular outcome on thaw. Factors such as storage time, patient age, and gender are considered in terms of cryopreservation and thawing outcomes. Cryopreserved leukapheresis samples from 41 donors, frozen by the same protocol and stored for up to 17 years, have been thawed using automated, water-free equipment and by conventional wet thawing using a water bath. Post-thaw viability, assessed by both trypan blue and flow cytometry, showed no significant differences between the techniques. Similarly, there was no negative effect of the duration of frozen storage, donor age at sample collection or donor gender on post-thaw viability using either thawing method. The implication of these results is that the cryopreservation protocol chosen initially remains robust and appropriate for use with a wide range of donors. The positive response of the samples to water-free thawing offers potential benefits for clinical situations by removing the subjective element inherent in water bath thawing and eliminating possible contamination issues.

Indexed as

AdultAgedAutomationBiomarkersCryopreservationFemaleHematopoietic Stem CellsHumansLeukapheresisLymphoma, Non-HodgkinMaleMiddle AgedMultiple MyelomaTime FactorsWaterBiomarkersWater

Identifiers

PMID33104704
PMCPMC7588046
OpenAlexW3093896468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.